Genprex provides clinical study updates for its Acclaim 1 and 3 trials

Genprex (GNPX) announced positive clinical study updates for its Acclaim-1 and Acclaim-3 clinical trials for the treatment of non-small cell lung cancer, or NSCLC, and small cell lung cancer, or SCLC, respectively, and plans to re-focus its oncology clinical development program. Patients in the Company’s lung cancer clinical trials are being treated with the Company’s lead drug candidate, Reqorsa, or quaratusugene ozeplasmid, Gene Therapy. Two patients in the Acclaim-1 study have had prolonged Progression Free Survival, or PFS, and importantly, the first treated patient in the Acclaim-3 study attained a Partial Remission, or PR, from the start of maintenance therapy. Ryan Confer, President and CEO, commented on the update: “We are excited by these early and promising patient responses to REQORSA treatment, particularly as these patients represent some of the most difficult to treat lung cancer patient populations. There is significant unmet medical need for patients afflicted with lung cancer, as nearly all patients’ disease progresses following treatment, even when treated with today’s most advanced targeted therapies and immunotherapies. This leaves patients with limited therapeutic options. We are thrilled our novel gene therapy treatment for lung cancer, REQORSA, is demonstrating early evidence of efficacy with a favorable safety profile. We look forward to continuing to evaluate REQORSA in our lung cancer clinical trials while we advance our efforts to bring new therapies to those battling cancer.” The Acclaim-1 clinical trial is evaluating the combination of REQORSA and AstraZeneca’s (AZN) Tagrisso to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso. The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech’s Tecentriq as a maintenance therapy to treat patients with extensive stage small cell lung cancer who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Confer and the executive team have evaluated resource allocations to ensure streamlined, focused strategies to support expeditious regulatory submissions for REQORSA and will implement the following changes to the Company’s oncology clinical development plans in order to prioritize resources and focus on the most promising aspects of the Acclaim-1 and Acclaim-3 lung cancer clinical trials.